MedTrace Logo

Pentoxifylline and Systemic Inflammation in Hemodialysis Patients

NCT01269827 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-12-19

No results posted yet for this study

Summary

The aim of this study was to compare the effect of PTX vs placebo on serum concentrations of TNF-α, IL-6, and CRP in patients on hemodialysis.

Conditions

Interventions

DRUG

Pentoxifylline

Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)

DRUG

starch tablets

Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)

Sponsors & Collaborators

  • Coordinación de Investigación en Salud, Mexico

    lead OTHER_GOV

Principal Investigators

  • Alfonso M. M Cueto-Manzano, MD, MSc, PhD · Unidad de Investigación Médica en Enfermedades Renales, Hospital de Especialidades, CMNO, IMSS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01269827 on ClinicalTrials.gov